Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers By Ogkologos - February 3, 2026 71 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase Ib/II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Elections 2021: What the results mean for people with cancer May 11, 2021 Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... September 7, 2021 After Being Told a Lump Was Benign, Teenager Learns She Has... August 14, 2021 Motivational Speaker Shares Her 11-Year Battle With Breast Cancer In New... November 16, 2021 Load more HOT NEWS Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... Woman Showed Up To Their Wedding And Stole All Their Gifts.... Misdiagnosis: Her Doctor Dismissed Her Concerns For Months Then Told Her... Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer
